Paradigm Biopharmaceuticals Limited ( ASX:PAR – Get Rating ) insider Paul Rennie purchased 73,851 shares of the company's stock in a transaction dated Friday, May 12th. The shares were purchased at an average price of A$1.03 ($0.69) per share, for a total transaction of A$75,992.68 ($51,001.80). Paradigm Biopharmaceuticals Price Performance The company has a debt-to-equity ratio of 0.53, a current ratio of 5.89 and a quick ratio of 5.93. ( Get Rating ) Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia.

https://www.dailypolitical.com/2023/05/20/paradigm-biopharmaceuticals-limited-asxpar-insider-buys-a75992-68-in-stock.html

#dailypolitical